Latanoprost Eg (Latanoprost)

Latanoprost activates prostaglandin F‑type receptors in the eye, which remodels the extracellular matrix of the ciliary body. This process increases the uveoscleral outflow of aqueous humor, allowing fluid to drain more efficiently and thereby reducing intra‑ocular pressure.

The prescribed dose of latanoprost is determined by the treating ophthalmologist. Typically, a single drop is instilled into the affected eye(s) once daily in the evening, but the exact regimen should follow the clinician’s written instructions.

Safety data for latanoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Latanoprost Eg, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and a favorable efficacy profile compared with beta‑blockers or carbonic anhydrase inhibitors. It often provides greater IOP reduction with a different side‑effect spectrum, such as increased eyelash growth, but individual response varies.

Latanoprost Eg should be stored at room temperature, below 25 °C, in its original packaging. Protect the bottle from direct light and moisture. Do not freeze the solution, and keep the dropper tip clean to avoid contamination.

Latanoprost Eg is applied as a single drop into the conjunctival sac of the affected eye(s) once daily, preferably in the evening. The patient should wash their hands, avoid touching the tip of the bottle to the eye or any surface, and close the eye gently after instillation.

Serious risks, though rare, include severe allergic reactions, uveitis, macular edema, paradoxical increase in intra‑ocular pressure, and corneal edema. Patients should seek immediate medical attention if they experience sudden vision loss, eye pain, redness, or swelling.

Latanoprost Eg should be avoided in patients with active ocular infections, known hypersensitivity to latanoprost or any component of the formulation, and in individuals with a history of severe ocular inflammation unless specifically directed by an ophthalmologist.